Emergent BioSolutions (NYSE:EBS) Cut to “Hold” at StockNews.com

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research report released on Friday.

A number of other equities research analysts also recently weighed in on EBS. Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, January 21st.

Emergent BioSolutions Stock Performance

Emergent BioSolutions stock opened at $11.61 on Friday. The firm’s 50 day simple moving average is $9.39 and its 200 day simple moving average is $9.31. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $15.10. The firm has a market capitalization of $629.19 million, a PE ratio of -2.83 and a beta of 1.60.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $293.80 million for the quarter, compared to the consensus estimate of $328.72 million. During the same quarter last year, the business posted ($1.44) earnings per share. As a group, analysts expect that Emergent BioSolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Emergent BioSolutions

A number of hedge funds have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC bought a new position in shares of Emergent BioSolutions during the 2nd quarter valued at $93,000. Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions in the third quarter worth about $96,000. FORA Capital LLC bought a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at about $103,000. Landscape Capital Management L.L.C. purchased a new stake in Emergent BioSolutions during the 3rd quarter valued at about $141,000. Finally, Entropy Technologies LP purchased a new position in Emergent BioSolutions in the 3rd quarter worth approximately $155,000. 78.40% of the stock is currently owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.